Application of compound T0349 in the preparation of anti-mycobacterium tuberculosis drugs
The interaction of M. tuberculosis FtsZ/SepF was blocked by compound T0349, and the problem of poor treatment of existing anti-tuberculosis drugs on drug-resistant strains was solved, effective inhibition of M. tuberculosis was achieved, and new treatment was provided Tuberculosis method.
Patent Information
- Application Number
- CN202110773577.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-07-08
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-07-08
AI Technical Summary
The existing anti-tuberculosis drugs have limited therapeutic effects on drug-resistant Mycobacterium tuberculosis and have high side effects, which leads to increased difficulty in treatment. Especially when HIV and TB are co-infected, there is a lack of target drugs for FtsZ/SepF interactions.
The compound T0349 was developed to specifically block the interaction of M. tuberculosis FtsZ/SepF and inhibit its growth. It is used to prepare anti-tuberculosis drugs and combine other drugs for combination drugs. It is suitable for different dosage forms and routes of administration.
Compound T0349 significantly inhibits the growth of Mycobacterium tuberculosis, and especially shows anti-activity better than first-line drugs against multidrug-resistant strains, providing a new potential means for treating tuberculosis and reducing treatment pressure.
Smart Images

Figure QLYQS_1 
Figure BDA0003153382990000021 
Figure BDA0003153382990000022
Abstract
Description
Technical Field
[0001] The present invention relates to the application of compound T0349 in the preparation of anti-mycobacterium tuberculosis drugs, and belongs to the field of medical biotechnology. Background Art
[0002] Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb). It has a high incidence and seriously endangers human health. Tuberculosis is mainly pulmonary tuberculosis and is transmitted through the respiratory tract. The main clinical symptoms are fever, fatigue, night sweats, and hemoptysis.
[0003] On October 14, 2020, the World Health Organization released the "2020 Global Tuberculosis Report". According to the report, in 2019, there were about 10 million new tuberculosis patients worldwide and about 1.41 million deaths from tuberculosis. Among them, there were about 833,000 new tuberculosis patients in China, ranking third in the world, second only to India and Indonesia. [1] However, the four first-line anti-tuberculosis drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) and eight second-line anti-tuberculosis drugs (streptomycin, ethionamide, para-aminosalicylic acid, capreomycin, kanamycin, ofloxacin, amikacin and cycloserine) currently used in clinical practice were all discovered between the 1940s and 1970s. In the past half century, only two new anti-tuberculosis drugs, bedaquiline and delamanid, have been approved for marketing by the US FDA and the European EMA, respectively. [2,3] However, due to the serious side effects and high prices of these two drugs, their application scope is greatly limited. Although there are several anti-tuberculosis drugs in the clinical research stage, their efficacy and side effects still need to be investigated.
[0004] In recent years, the emergence and spread of drug-resistant Mycobacterium tuberculosis and the co-infection of HIV and Mycobacterium tuberculosis have brought greater challenges to the treatment of tuberculosis. According to WHO estimates, in 2019, about 3.3% of new tuberculosis patients and 18% of retreated tuberculosis patients were resistant to rifampicin. [1] The treatment of drug-resistant tuberculosis generally requires the combined use of 5-6 drugs, with many types of drugs and a long treatment cycle. The incidence of adverse drug reactions is higher than that of ordinary tuberculosis patients, making it difficult to treat. The co-infection of HIV and TB has further increased the burden of tuberculosis. [4] Therefore, the research and development of anti-tuberculosis drugs, especially the discovery of anti-drug-resistant tuberculosis drugs, plays a vital role in the prevention and treatment of tuberculosis.
[0005] The development of anti-tuberculosis drugs mostly targets the bacterial proteins of Mycobacterium tuberculosis. Bacterial FtsZ (Filamentous temperature-sensitive protein Z) is the equivalent protein of the mammalian structural protein tubulin and plays a key role in the bacterial mitosis process. The FtsZ protein has GTPase activity and can catalyze the hydrolysis of GTP to generate GDP. When bacteria divide, the FtsZ protein binds to GTP and hydrolyzes GTP to provide power. FtsZ self-polymerizes into polymers to form the Z ring, and the Z ring acts as a skeleton to recruit a variety of other bacterial division proteins such as FtsA, ZipA, EzrA, SepF, etc. to form a division complex. [5] This fission complex can cause the cell membrane to shrink. Eventually, a septum is formed in the middle of the cell, and the two newly formed cells are separated by hydrolyzing the peptidoglycan in the bacterial cell septum. SepF is a bacterial fission protein unique to Bacillus subtilis and Mycobacterium, and plays an important role in the bacterial mitosis process. [6] SepF can interact with the C-terminus of FtsZ to form a tight complex, rivet the self-aggregated polymer of FtsZ to the cell membrane, and promote the contraction of the cell membrane and the formation of the partition [7] Bacterial fission proteins are indispensable in the process of bacterial division, and their structures are relatively conservative and not prone to mutation, making them the most promising drug targets. FtsZ / SepF interaction is unique to mycobacteria, and there are currently no reports of anti-tuberculosis drugs targeting FtsZ / SepF interaction. We believe that targeting the FtsZ / SepF interaction of Mycobacterium tuberculosis can screen for specific anti-tuberculosis active compounds with different mechanisms of action.
[0006] By screening 2000 samples of the compound library (purchased from J&K) for the Mycobacterium tuberculosis FtsZ / SepF interaction inhibitor screening model, we found the positive compound T0349, which can specifically block the Mycobacterium tuberculosis FtsZ / SepF interaction. We also tested the anti-tuberculosis activity of compound T0349 and found that T0349 can effectively inhibit the growth of Mycobacterium tuberculosis.
[0007] A search of the Scifinder database did not find any reports on the anti-tuberculosis activity and other biological activities of compound T0349. Summary of the invention
[0008] The present invention provides use of compound T0349 or a pharmaceutically acceptable salt thereof as shown in structural formula (I) in the preparation of a drug for preventing or treating Mycobacterium tuberculosis.
[0009]
[0010] In the above application, the drug is a pharmaceutical composition with the compound T0349 represented by structural formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
[0011]
[0012]
[0013] In the above application, the pharmaceutical composition also contains other anti-Mycobacterium tuberculosis drugs.
[0014] In the above application, the anti-Mycobacterium tuberculosis effect is achieved by inhibiting the FtsZ / SepF interaction in Mycobacterium tuberculosis, thereby exerting its activity of inhibiting the growth of Mycobacterium tuberculosis.
[0015] In the above application, the Mycobacterium tuberculosis includes the standard strain H37Rv and the clinical drug-resistant strain MDR16559.
[0016] The pharmaceutical composition can be prepared according to methods known in the art. Any dosage form suitable for human or animal use can be prepared by combining the compound of the present invention with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants. The content of the compound of the present invention in other pharmaceutical compositions is usually 0.1-95% by weight.
[0017] The compounds of the present invention or other pharmaceutical compositions containing them can be administered in unit dosage form, and the administration route can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0018] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w types, w / o types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0019] The compound of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various micro-advantage drug delivery systems.
[0020] In order to prepare the compound of the present invention into tablets, various excipients known in the art can be widely used, including diluents, adhesives, wetting agents, disintegrants, lubricants, and glidants. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent can be water, ethanol, isopropanol, etc.; the binder can be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, coach sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant can be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0021] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0022] In order to prepare the dosing unit into a capsule, the active ingredient compound of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient compound of the present invention can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. Various diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.
[0023] To prepare the compound of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc. The osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0024] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.
[0025] The inventors of the present invention have found that compound T0349 can specifically block the binding between the FtsZ protein and the SepF protein of Mycobacterium tuberculosis, thereby inhibiting the growth of Mycobacterium tuberculosis. It can also be used in combination with other anti-Mycobacterium tuberculosis drugs.
[0026] In order to achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known administration method.
[0027] The dosage of the pharmaceutical composition of the compound of the present invention may vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form. Generally speaking, the suitable daily dosage range of the compound of the present invention is 0.001-150 mg / kg body weight, preferably 0.1-100 mg / kg body weight, more preferably 1-60 mg / kg body weight, and most preferably 2-30 mg / kg body weight. The above dosage unit may be divided into several dosage units for administration, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment means.
[0028] The compound or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
[0029] Beneficial technical effects
[0030] Tuberculosis caused by Mycobacterium tuberculosis is difficult to treat, with a high incidence rate, and the treatment of drug-resistant tuberculosis faces even greater difficulties. The research and development of new anti-tuberculosis drugs has been slow in recent decades. Compound T0349 has a novel target, good anti-mycobacterium tuberculosis effect, and good anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis. The present invention will help alleviate the pressure of tuberculosis treatment and serve as a potential new means of disease prevention and treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Schematic diagram of the screening principle.
[0032] Figure 2 Inhibitory effect of compound T0349 on β-gal activity in the screening model AH109 (pAD-FtsZ+pBD-SepF). DETAILED DESCRIPTION
[0033] Experimental Example 1: Principle of the Mycobacterium tuberculosis FtsZ / SepF interaction inhibitor screening model
[0034] A screening model for inhibitors of the FtsZ / SepF interaction of Mycobacterium tuberculosis was established using the yeast two-hybrid system. In the yeast two-hybrid system, GAL4 is an important transcriptional activator of Saccharomyces cerevisiae, which is divided into two parts: the DNA-binding domain (BD) and the transcriptional activation domain (AD). BD and AD can exist independently. When the two are close to each other in spatial position, they can fuse into a complete GAL4 transcriptional activator to activate the expression of the downstream gene lacZ. Taking advantage of this feature, we fused FtsZ and SepF with AD and BD, respectively. When FtsZ / SepF interact, AD and BD can be fused and expressed as a complete GAL4 transcription factor, thereby activating the expression of its downstream reporter gene lacZ and producing β-galactosidase (β-gal), which is manifested as β-gal activity. Therefore, by identifying the activity of β-gal, it can be determined whether FtsZ / SepF interacts. When small molecule compounds blocked the FtsZ / SepF interaction, the expression of the reporter gene lacZ was inhibited and the activity of the expression product of LacZ, β-gal, was reduced.
[0035] In the experiment, the FtsZ and SepF proteins of Mycobacterium tuberculosis were fused with AD and BD respectively to construct plasmids pAD-FtsZ and pBD-SepF, and then the two plasmids were co-transformed into yeast AH109 to construct the AH109 (pAD-FtsZ+pBD-SepF) screening model. In this screening system, if the compound can block the interaction between the FtsZ and SepF proteins of Mycobacterium tuberculosis, the expression of the reporter gene lacZ will be inhibited and the activity of β-gal will be reduced. The screening principle is as follows Figure 1 shown.
[0036] Experimental Example 2: Study on the activity of compound T0349 in the Mycobacterium tuberculosis FtsZ / SepF interaction inhibitor screening model
[0037] We used the model bacteria AH109 (pAD-FtsZ + pBD-SepF) as the experimental group, and set up the control bacteria AH109 (pAD-T + pBD-53) (T and p53 are known to interact with each other). The model bacteria AH109 (pAD-FtsZ + pBD-SepF) and the control bacteria AH109 (pAD-T + pBD-53) were cultured in SD / -Trp-Leu-His-Ade medium at 30°C overnight until the logarithmic growth phase, and the OD 600=0.6-0.8, diluted with corresponding culture medium at a ratio of 1:100. Compound T0349 (purchased from J&K) was added to the model bacteria AH109 (pAD-FtsZ+pBD-SepF) and the control bacteria AH109 (pAD-T+pBD-53) to a final concentration of 0.625, 1.25, 2.5, 5, 10, 20 μM, 30°C, overnight culture, collected bacteria, and resuspended with culture medium. Take 70 μL (V) of the resuspended bacteria and place them in a 96-well transparent plate, set up a culture medium control group, and measure the absorbance OD at 660 nm 600 Mix Y-PER and 2×Galactosidase Assay Buffer 1:1, take 70μL and add it to the bacteria, incubate at room temperature, and record the color development time (t). After color development, add 56μL of reaction stop solution, mix well, and measure the absorbance OD at 420nm. 420 . Calculate the activity of β-gal.
[0038] The calculation formula is as follows:
[0039] β-gal=1000×OD 420 / t×V×OD 600 (t = color development time; V = bacterial volume)
[0040] The specific inhibition rate of T0349 on β-gal in the model bacteria AH109 (pAD-FtsZ+pBD-SepF) at different concentrations was further calculated.
[0041] The active compound T0349, whose chemical structure is tetrahydro-α1,α4-bis[(2-naphthalenyloxy)methyl]-1H-1,4-diazepine-1,4(5H)-diethanol, can significantly inhibit the expression of the reporter gene LacZ of the model bacteria AH109 (pAD-FtsZ+pBD-SepF), which is manifested by a dose-dependent decrease in β-gal activity. However, compound T0349 has no effect on the reporter gene β-gal of the control bacteria AH109 (pAD-T+pBD-53). This proves that compound T0349 can specifically block the interaction between FtsZ and SepF. Figure 2 The inhibitory effect of compound T0349 on β-gal activity in the screening model AH109 (pAD-FtsZ+pBD-SepF).
[0042] Experimental Example 3: Anti-Mycobacterium tuberculosis activity of compound T0349
[0043] The anti-tuberculosis activity was detected by the Microdilution Alamar Blue Assay (MABA) method. The standard strain H37Rv and the clinical multidrug-resistant strain MDR16559 were selected as the Mycobacterium tuberculosis strains. The concentration of Mycobacterium tuberculosis cells was adjusted to 10 6 CFU / mL, cultured in 96-well plates with 7H9 medium, 200μL per well. Compound T0349 was dissolved in DMSO to a final concentration of 1mg / mL. The drug detection concentrations of MIC were: 16, 8, 4, 2, 1, 0.5, 0.25, 0.125μg / mL. At the same time, first-line anti-tuberculosis drugs rifampin (Rifampin) and isoniazid (Isoniazid) were set up as controls. Incubate at 37℃ for 7 days, add 20μL 10×Alamar Blue and 5% Tween-80 50μL mixed solution, incubate at 37℃ for another 24h, and observe the color change of the culture wells. MIC is defined as the lowest drug concentration in the culture well that changes from blue to pink.
[0044] The results showed that the MIC of compound T0349 against the standard strain of Mycobacterium tuberculosis H37Rv and the clinical multidrug-resistant strain MDR16559 was 1 μg / mL, and its inhibitory activity against the clinical multidrug-resistant strain MDR16559 was better than that of the first-line anti-tuberculosis drugs rifampicin (4 μg / mL) and isoniazid (16 μg / mL) (Table 1). Compound T0349 showed good anti-drug-resistant tuberculosis activity
[0045] Table 1 Anti-tuberculosis activity of compound T0349
[0046]
[0047] References:
[0048] 1.WHO.Global tuberculosis report 2020.World Health Organization 2020.
[0049] 2. Nagabushan H, Roopadevi H S. Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis. Journal of Postgraduate Medicine, 2014, 60(3): 300-302.
[0050] 3.Blair H A,Scott L J.Delamanid:a review of its use in patients withmultidrug-resistant.
[0051] 4.Dheda K,Maartens G.Tuberculosis.Lancet,2016,387(10024):1211-1226.
[0052] 5.Cristina O,Paolo N,Laura C,et al.The keepers of the ring:regulatorsof FtsZ assembly.Fems Microbiology Reviews,2016(1):57.
[0053] 6.Hamoen L W,Meile J C,Jong W D,et al.SepF,a novel FtsZ-interactingprotein required for a late step in cell division.Molecular Microbiology,2010,59(3):989-999.
[0054] 7.Gupta S,Banerjee S K,Chatterjee A,et al.Essential protein SepF ofmycobacteria interacts with FtsZ and MurG to regulate cell growth anddivision.Microbiology,2015:mic.0.000108。
Claims
1. Use of the compound T0349 represented by structural formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating Mycobacterium tuberculosis infection, 2. The use according to claim 1, characterized in that: The Mycobacterium tuberculosis are the standard strain H37Rv and the clinical drug-resistant strain MDR16559.
